Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.


Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies




The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

Study Status: Completed


Condition Intervention Phase
Solid Malignancies Drug: Ixabepilone Phase 1

Verified by Bristol-Myers Squibb December, 2009

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb identifier: NCT00162136

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Bristol-Myers Squibb., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site